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The comparative effectiveness 
of mpMRI and MRI‑guided 
biopsy vs regular biopsy 
in a population‑based PSA testing: 
a modeling study
Abraham M. Getaneh*, Eveline A. M. Heijnsdijk & Harry J. de Koning
The benefit of prostate cancer screening is counterbalanced by the risk of overdiagnosis and 
overtreatment. The use of a multi‑parametric magnetic resonance imaging (mpMRI) test after a 
positive prostate‑specific antigen (PSA) test followed by magnetic resonance imaging‑guided biopsy 
(MRIGB) may reduce these harms. The aim of this study was to determine the effects of mpMRI and 
MRIGB vs the regular screening pathway in a population‑based prostate cancer screening setting. A 
micro‑simulation model was used to predict the effects of regular PSA screening (men with elevated 
PSA followed by TRUSGB) and MRI based screening (men with elevated PSA followed by mpMRI 
and MRIGB). We predicted reduction of overdiagnosis, harm‑benefit ratio (overdiagnosis per cancer 
death averted), reduction in number of biopsies, detection of clinically significant cancer, prostate 
cancer death averted, life‑years gained (LYG), and quality adjusted life years (QALYs) gained for 
both strategies. A univariate sensitivity analysis and threshold analysis were performed to assess 
uncertainty around the test sensitivity parameters used in the MRI strategy.In the MRI pathway, we 
predicted a 43% reduction in the risk of overdiagnosis, compared to the regular pathway. Similarly 
a lower harm‑benefit ratio (overdiagnosis per cancer death averted) was predicted for this strategy 
compared to the regular screening pathway (1.0 vs 1.8 respectively). Prostate cancer mortality 
reduction, LY and QALYs gained were also slightly increased in the MRI pathway than the regular 
screening pathway. Furthermore, 30% of men with a positive PSA test could avoid a biopsy as 
compared to the regular screening pathway. Compared to regular PSA screening, the use of mpMRI 
as a triage test followed by MRIGB can substantially reduce the risk of overdiagnosis and improve the 
harm‑benefit balance, while maximizing prostate cancer mortality reduction and QALYs gained.
The standard and widely used method for the detection of prostate cancer is offering transrectal ultrasound-
guided biopsy (TRUSGB) for men with an elevated PSA level or abnormal digital rectal examination (DRE). 
However, this classical pathway is associated with an underdetection of clinically significant/high-grade prostate 
cancer and overdetection of clinically insignificant /low-grade prostate  cancer1, which can lead to an unnecessary 
biopsy, overdiagnosis, and overtreatment. The TRUSGB is also associated with a higher rate of misclassifica-
tion of grades as compared to magnetic resonance imaging-guided biopsy (MRIGB) that can lead to under or 
 overtreatment2. Furthermore, TRUSGB is associated with increased risk of complications like bleeding and 
 pain3, which can lead to increased health care costs and even-life threatening  sepsis4. Therefore, looking for an 
alternative diagnostic pathway that can minimize the risk of overdiagnosis and maximizes the prostate cancer 
mortality reduction should be at urge.
Using a multi-parametric magnetic resonance imaging (mpMRI) as a triage test followed by MRIGB may 
reduce the risk of overdiagnosis and overtreatment. Several studies reported that the use of mpMRI and MRIGB 
is superior to a regular  pathway1,5,6. The MRI pathway is characterized by having high sensitivity for clinically 
significant prostate cancer, and low sensitivity for insignificant  cancer7–9, and reduces misclassification rate of 
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grade at biopsy compared to  TRUSGB2. Furthermore, by using this pathway, a substantial amount of unneces-
sary biopsies can be  avoided6.
Although various studies reported that the use of mpMRI and MRIGB can reduce the detection of indolent 
prostate cancer, there is no study so far that quantifies the exact effect of this strategy on the risk of overdiagnosis 
as well as its effect on prostate cancer related death. However, estimation of the long-term effects of screening 
such as overdiagnosis is unlikely from trial data. Therefore, the aim of this modeling study was to determine the 
effects of mpMRI and MRIGB as compared to TRUSGB in a population-based prostate cancer screening setting.
Materials and methods
MISCAN model. The micro-simulation screening analysis (MISCAN) prostate cancer  model10–12 was used 
to evaluate the long-term effects of prostate cancer screening using regular pathway (positive PSA test followed 
by TRUSGB) vs MRI pathway (positive PSA test followed by mpMRI and MRIGB). Microsimulation is a mod-
eling technique that typically uses a large sample size of individual units (microunits), each with a unique set of 
attributes, and allows for simulations of downstream events on the basis of predefined states and the transition 
probabilities between those states over  time13. Likewise, MISCAN prostate model is a stochastic model that 
simulates individual life histories, natural history of prostate cancer, effect of treatment at baseline (without 
screening), and the effect of screening. Each individual in the simulation starts with no prostate cancer, and 
through time there is a chance to transit to preclinical prostate cancer. There are eighteen pre-clinical detectable 
states with a combination of three stages (T1, T2, and T3), three Gleason scores (7, less than 7, and greater than 
7), and two metastatic states (whether or not the cancer is metastasized). From each pre-clinical state, the tumors 
can progress to a more advanced state, can be clinically diagnosed, or be screen detected (Appendix_Figure S1).
After detection, the person is assigned to either radical prostatectomy (RP), radiation therapy (RT), or 
Active surveillance (AS). Distribution of the treatments depends on age, stage, and Gleason score as described 
 before14–16. Baseline survival (in the absence of treatment) from a clinical diagnosis of prostate cancer was 
modeled by fitting a Cox model to Surveillance, Epidemiology, and End Results (SEER) survival data from the 
pre-PSA era (1983–1986), as described in a previous  study14. The effect of treatment on survival for localized 
prostate cancer cases was modeled using a hazard ratio of 0.56 for those who received RP as compared with those 
without  treatment17. The same effect was assumed for RT. For metastasized prostate cancer cases, it was assumed 
that palliative treatment has no effect on survival.
The benefit of PSA screening on prostate cancer mortality was modeled using a lead time dependent cure 
probability (mortality benefit increases with lead time). Lead time is the years by which detection of the cancer 
is advanced by screening compared with the clinical  situation16. If a man is cured, he will not die from prostate 
cancer; but if he is not cured the date and cause of death are not changed due to earlier detection by screening. 
Death from other causes was modeled based on Dutch life  table18.
The MISCAN prostate model was calibrated to European Randomized Study of Screening for Prostate Cancer 
(ERSPC) data as has been described  before12. In order to account the younger age groups (50–54 years), the 
model was also calibrated to prostate cancer incidence among the Dutch population between 1989 and 2013 
from age 50 to age 75 (5-years categories), and the observed prostate cancer mortality over the same period was 
used for  validation19. Further descriptions about the four components of MISCAN prostate model (demography, 
natural history, screening and treatment) can be found at https ://cisne t.flexk b.net/mp/pub/CISNE T_Model Profi 
le_PROST ATE_ERASM US_001_12152 009_69754 .pdf.
Screening strategy. In our previous study, we compared more than 200 population-based prostate cancer 
screening strategies, and we found that screening with 3 years interval at ages 55–64 would be the optimum 
screening  strategy19. All men with an elevated serum PSA level (cut-off 3 ng/mL) were referred to TRUSGB in 
that study. Those who were positive at TRUSGB were assigned to either RP, RT or AS according to the treatment 
distribution mentioned before. The biopsy compliance rate after a positive screen test result was assumed to be 
90%, with a sensitivity of 90% as observed in the ERSPC Rotterdam  data20,21. An 80% screening attendance rate 
was assumed. The total number of biopsies was calculated by using the number of screen detected cancers and a 
mean positive predictive value of 22.7% of a biopsy in the screen arm of the  ERSPC21 and by using the number of 
clinically detected cancers and the positive predictive value of 35.8% of a biopsy in the control  arm22.
In the present study, we included mpMRI as a triage test to this screening strategy (screening with 3-year 
intervals at ages 55–64) for those men with an elevated PSA level (cut-off 3 ng/mL) before referring them to a 
biopsy (MRIGB) (Fig. 1). PIRADS scores of 3–5 were considered positive for the mpMRI test. It is important 
to note that we did not use a combined biopsy, rather those men with positive mpMRI tests were subjected 
only to an MRI-guided biopsy (no systematic biopsy). The same screening attendance and biopsy compliance 
were assumed as in the regular pathway. A positive predictive value of 58%23 was assumed to calculate the total 
number of biopsies in this strategy. Men positive at MRIGB were assigned to the same treatment options as in 
TRUSGB. Grade specific sensitivity values for mpMRI and MRIGB were mainly based on literature that used 
meta-analysis (Table 1). Although a very recent meta-analysis reported by Drost et al.24 was not included in our 
study, most of the test sensitivity parameter values reported in that study are within the range of the values that 
we used for our sensitivity analysis. We also accounted for misclassification of grades both in the MRIGB and 
regular biopsy. In our study misclassification of grades represents only wrong classification of clinically signifi-
cant cancer in to insignificant cancer at biopsy. For the MRIGB we used an 8.7% misclassification rate based 
on Ahdoot et al.2. For the regular biopsy 16.8%, 36.3% and 60% of misclassification were  reported2,25,26, and we 
used the intermediate 36.3%.
We compared the two strategies in terms of a harm-benefit ratio (overdiagnosis per death averted), reduction 
of overdiagnosis, reduction of number biopsied, detection of clinically significant cancer, death averted, life-years 
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gained, life-years gained (LYG) per death averted, QALYs gained and QALYs gained per death averted. In this 
study, clinically significant prostate cancer was defined as Gleason score 7 or more and clinically insignificant 
cancer as Gleason score 6 and  less5. In both screening strategies, a hypothetical cohort of 10 million men was 
simulated over a lifetime period. All the results are reported per 1000 men.
Quality of life. The quality adjusted life-years (QALYs) were calculated based on the utility estimates of 
given health states where patients remain for a certain period of time. The utility values range between 0 (death) 
and 1 (perfect health), and one minus the utility value gives a loss in utility at each health state. By multiplying 
the number of men in a given health state with the loss in utility and the duration of the health state, the loss 
in quality of life was calculated. The utility estimate (0.96) and duration (1 week) for mpMRI were based on 
Grana et al.27. There is evidence that MRIGB is associated with less frequent adverse outcomes compared with 
 TRUSGB3. Therefore, we assumed 50% lower disutility for MRIGB compared with that of TRUSGB. All other 
utilities and durations were based on our previous  study12 (Appendix_Table S1).
Sensitivity analysis. To check the robustness of our results, we performed a one-way sensitivity analysis 
on the harm-benefit ratio (overdiagnosis per death averted) of the MRI pathway. Because the performance and 
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Figure 1.  Schematic representation of the MRI pathway (M) and regular pathway (R). mpMRI multi parametric 
magnetic resonance imaging, MRIGB magnetic resonance imaging-guided biopsy, MRI magnetic resonance 
imaging, TRUSGB transrectal ultrasound-guided biopsy.
Table 1.  Sensitivity values for the MRI pathway used in the model. mpMRI multi parametric magnetic 
resonance imaging, MRIGB magnetic resonance imaging-guided biopsy. a Used as a sensitivity of mpMRI for 
low grade cancer in our model.
Variable Value References
Sensitivity of mpMRI for high grade cancer 0.94 (range 0.70–0.97) Sathianathen et al.37
Overall sensitivity of  mpMRIa 0.74 (95% CI 0.66–0.81) de Rooij et al.38
Sensitivity of MRIGB for low grade cancer 0.44 (95% CI 0.26–0.64) Schoots et al.29
Sensitivity of MRIGB for high grade cancer 0.91 (95% CI 0.87–0.94) Schoots et al.29
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interpretation of both mpMRI and MRIGB are highly influenced by the specialists (radiologist or urologist) 
skills, we varied the test sensitivity parameters for the analysis using the 95% confidence intervals indicated in 
Table 1. A threshold analysis was also performed on QALYs per death averted by changing the baseline sensitiv-
ity values of the mpMRI and MRIGB simultaneously.
Ethics declarations. No human or animal subjects are involved in this study (it is a modeling study).
Results
Base model. The total numbers of men referred to a biopsy were 396 and 278 for the regular and the MRI 
pathway respectively, a 30% reduction (Table 2). Our model predicted 16 overdiagnosed cases for the regular 
pathway and 9 (43% reduction) for the MRI pathway (overdiagnosed cancer was defined as a prostate cancer 
detected during screening but would not have been clinically diagnosed during the man’s life time in the absence 
of screening). The model predicted a 2.7% higher prostate cancer mortality reduction for the MRI pathway than 
the regular pathway (8.77 vs 8.53). The MRI based screening was also associated with a lower harm-benefit ratio 
(overdiagnosis per cancer death averted) than the regular screening (1.0 vs 1.8). Our model predicted a higher 
LY gained (85 vs 81.6) and QALYs gained (80.2 vs 77) in the MRI pathway than the regular screening pathway.
Clinically significant prostate cancer was detected in 51.3 men in the MRI pathway, as compared with 36 in 
the regular pathway (30% increment in the detection rate of clinically significant prostate cancer). In contrary, 
fewer men were diagnosed with clinically insignificant prostate cancer in the MRI pathway than the regular 
pathway (59 vs 80.8), which resulted in a 27% reduction. However, the MRI pathway was also associated with an 
11% risk of missing clinically significant cancer due to not performing biopsy in the mpMRI negative patients.
Sensitivity analysis. After varying the baseline sensitivity values of the MRI pathway, using the 95% con-
fidence intervals or ranges, the harm-benefit ratio (overdiagnosis per death averted) remained lower in the MRI 
pathway than the baseline value (1.8) of the regular pathway (Fig. 2). The threshold analysis indicated that when 
the baseline test sensitivity values of the MRI pathway were changed by 14% simultaneously, the QALYs/death 
averted became the same for the two strategies (Fig. 3). To be the QALYs per death averted in favour of the MRI 
pathway, the sensitivity of mpMRI and MRIGB for clinically significant prostate cancer should be higher than 
81% and 78% respectively; whereas, for that of clinically insignificant prostate cancer it should be lower than 
84% and 50% respectively.
Discussion
The benefit of prostate cancer screening in reducing advanced stage disease or mortality is counterbalanced by 
the risk of overdiagnosis and  overtreatment28. In our study, when mpMRI was applied after a positive PSA test 
and followed by MRIGB, the risk of overdiagnosis was decreased substantially (by 43%) compared with the 
regular screening. This result can be taken confirmatory for previous studies that proposed the use of mpMRI 
and MRIGB as a potential means to reduce the risk of overdiagnosis. The lower harm-benefit ratio predicted in 
the present study could also inform policymakers about the role of MRI in a population-based prostate cancer 
screening.
When the MRI pathway was used instead of the regular pathway, 30% of men avoided biopsies. A recent study 
by Kasivisvanathan et al.5 reported a 28% biopsy reduction due to the use of mpMRI and MRIGB. As compared 
to the regular pathway, the MRI pathway was also associated with a 30% higher detection rate and 27% lower 
detection rate for clinically significant and insignificant prostate cancer, respectively. A meta-analysis29 concluded 
that MRIGB has a higher detection rate for clinically significant prostate cancer and a lower detection rate for 
insignificant cancer compared with TRUSGB. More specifically, Siddiqui et al.30 reported MRIGB increases the 
detection of high risk cancer by 30% (compared to TRUSGB), and Leest et al.31 indicated TRUSGB would over 
detect insignificant cancer in 20%. The number (percentage) of clinically significant cancers reported in our 
study (in both pathways) are lower than the number reported by Kasivisvanathan et al. 2018, who used the same 
definition. The main reason for this discrepancy could be the difference in population characteristics of the two 
studies. For instance, the upper age limit included in the present study was 64 years, whereas in Kasivisvanathan 
et al. 2018 the mean age was 64 ± 7. Therefore, the older age groups in the Kasivisvanathan et al. 2018 may con-
tribute to the higher number of high grade cancers (grade 7 and above) than reported in our study. Although 
it is difficult to directly compare our results with the above studies (because of differences such as, population 
characteristics, follow-up period and screening strategy), the general conclusion is the same: the use of mpMRI 
and MRI guided biopsy is superior over that of the regular pathway.
Using of the MRI pathway resulted in an increased LYG, QALYs gained, and prostate cancer death averted 
compared to the regular pathway. The increased in LYG and mortality benefit in the MRI pathway can be 
explained by the increased detection of clinically significant cancer (by about 30%), and the lower misclassifica-
tion rate of grades by MRIGB (compared to TRUSGB), that were included in our model. On the other hand, 
the lower detection rate of clinically insignificant cancer in the MRI pathway could explain the higher QALYs 
gained. However, the MRI pathway also failed to detect around 11% of clinically significant cancer, that would 
be detected in the regular pathway, and this could explain the smaller difference in mortality benefit between the 
two strategies. This percentage is in agreement with a previous study by Pokorny et al.6. The small QALYs differ-
ence reported between the two strategies may raise a question of whether the MRI-pathway can be an efficient 
strategy, especially in relation to the initial additional expenditures required in the MRI-pathway. However, a 
substantial amount of biopsies were avoided as a result of using the MRI pathway, and this could compensate 
for the additional expenditures.
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Our prediction of the lower harm benefit ratio (overdiagnosis per death averted) for the MRI pathway than 
the regular pathway was robust to the sensitivity analysis (Fig. 2). It is also important to note from the figure that, 
increasing the sensitivity of mpMRI and MRIGB for high grade cancer resulted in a more better harm benefit 
ratio, and lowering theses sensitivities relatively worse the ratio. In contrary, lowering the sensitivity of mpMRI 
and MRIGB for low grade cancer makes the ratio more better, and increasing these sensitivities makes the ratio 
relatively worse. The threshold analysis showed that when the baseline test sensitivity values of the MRI pathway 
were changed by 14% simultaneously (this means increasing the sensitivities of mpMRI and MRIGB for low 
grade cancer and decreasing for high grade cancer by 14% simultaneously), the QALYs per death averted became 
the same for the two strategies. This may signify the importance of adhering to proper imaging protocol as well 
Table 2.  Predictions of the effects of prostate cancer screening for men between age 55–64 at 3 years intervals 
using regular pathway and MRI pathway, per 1000 men. a Clinically insignificant cancer was defined as Gleason 
score 6 and below (it contains both screen detected and interval cancer). b Clinically significant prostate cancer 
was defined as Gleason score 7 or more (it contains both screen detected and interval cancer). c Overdiagnosed 
cancer was defined as a prostate cancer detected during screening but would not have been clinically diagnosed 
during the man’s life time in the absence of screening.
Regular pathway MRI pathway Difference
Number of men biopsied 396 278 118 (− 30%)
Total number of clinically  insignificanta cancer detected at biopsy 80.8 58.9 21.9 (− 27%)
Total number of  clinicallyb significant cancer detected at biopsy 36.0 51.3 15.3 (+ 29.8%)
Percent clinical significant cancer missed in the MRI-pathway due to reduction in 
biopsies – 10.8% –
Number  overdiagnosedc 15.6 8.9 6.7 (− 43%)
Number of prostate cancer deaths averted 8.53 8.77 0.24 (+ 2.7%)
Overdiagnosed cases per death averted 1.8 1.0 0.8 (− 44%)
Life-years gained 81.6 85.0 3.4 (+ 4%)
LY gained per death averted 9.57 9.70 0.13 (+ 3%)
Quality adjusted life-years gained 77.0 80.2 3.2 (+ 3.9%)
QALY gained per death averted 9.0 9.14 0.14 (+ 1.5%)
0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
sens. MRIGB high grade
sens. mpMRI low grade
sens. mpMRI high grade
sens. MRIGB low grade
Overdiagnosis per death averted in the MRI pathway
Upper bound
Lower bound
Figure 2.  Tornedo diagram of one-way sensitivity analysis on the harm-benefit ratio (over diagnosis per cancer 
death averted) for the MRI pathway. sens.MRIGB low grade- sensitivity of magnetic resonance imaging-guided 
biopsy for low grade prostate cancer; sens.MRIGB high grade- sensitivity of magnetic resonance imaging-
guided biopsy for high grade prostate cancer; sens.mpMRI low grade- sensitivity of multi-parametric magnetic 
resonance imaging for low grade prostate cancer; sens.mpMRI high grade- sensitivity of multi-parametric 
magnetic resonance imaging for high grade prostate cancer.
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as interpretation by the radiologist/urologist. A review by Stabile eta  al32 indicated that there are various factors 
affecting the performance of mpMRI and MRIGB, among these radiologists’ reading experience and urologists’/
radiologists’ biopsy experience were the main ones.
An important strength of this study is that we were able to quantify the effect of MRI based prostate cancer 
screening on the risk of overdiagnosis, which is obviously not observable in trial studies. We also quantified 
the effect of the MRI pathway on the harm-benefit ratio (overdiagnosis per death averted) as compared to the 
regular pathway, which was also not reported in previous studies. Furthermore, we were able to evaluate the 
MRI pathway in a population based screening setting. Although our model is calibrated to the Dutch prostate 
cancer incidence, the results may also be extrapolated to other western populations with similar prostate cancer 
incidence trends. Study shows that in Western Europe, the incidence of prostate cancer has been on the  rise33.
Our study has also certain limitations. First, we assumed the same mortality benefit for radiation therapy as 
that of radical prostatectomy, since there is no clinical trial that compared the two treatment directly. We also 
assumed that treatment options will not change in both strategies. However, treatment behavior may change in 
the future, such as more active surveillance than now. Cost is another important factor which was not included 
in this study. However, avoidance of biopsies and subsequent biopsy related complications and treatment costs, 
probably make the MRI pathway cost-effective or at least compensate its additional costs. Various studies, though 
not population-based studies, indicated that the inclusion of mpMRI after a positive PSA test followed by MRI-
guided biopsy is cost-effective compared to a regular prostate cancer screening  pathway34–36. Future studies are 
needed to evaluate this in a population-based screening settings. Lastly, a probabilistic sensitivity analysis was 
not included in our study: only a one-way sensitivity analysis and threshold analysis were included.
In conclusion, our modeling results indicated that the use of mpMRI after a positive PSA test followed by 
MRIGB can substantially reduce the risk of overdiagnosis and improve the harm-benefit ratio, while maximizing 
prostate cancer mortality reduction and QALYs gained, as compared to the regular screening pathway.
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